By Mill Chart
Last update: Jan 16, 2024
In this article we will dive into AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) as a possible candidate for growth investing. Investors should always do their own research, but we noticed AMPHASTAR PHARMACEUTICALS IN showing up in our CANSLIM growth screen, which makes it worth to investigate a bit more.
Every day, ChartMill assigns a Technical Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various technical indicators and properties.
We assign a technical rating of 7 out of 10 to AMPH. This is due to a consistent overall performance, although we see some doubts in the very recent evolution. In the medium time frame things are still looking good.
Our latest full technical report of AMPH contains the most current technical analsysis.
ChartMill assigns a Fundamental Rating to every stock. This score ranges from 0 to 10 and is updated daily. The score is determined by evaluating multiple fundamental indicators and properties.
We assign a fundamental rating of 7 out of 10 to AMPH. AMPH was compared to 204 industry peers in the Pharmaceuticals industry. While AMPH belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. AMPH is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make AMPH a good candidate for value and growth investing.
Check the latest full fundamental report of AMPH for a complete fundamental analysis.
More growth stocks can be found in our CANSLIM screen.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
AMPHASTAR PHARMACEUTICALS IN
NASDAQ:AMPH (4/19/2024, 7:00:00 PM)
After market: 40.1 +0.09 (+0.22%)40.01
+1.36 (+3.52%)
Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.